Immunic (NASDAQ:IMUX) Upgraded to “Strong-Buy” at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a report released on Monday morning, Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Leerink Partners reaffirmed an outperform rating and set a $5.00 price target on shares of Immunic in a report on Monday, September 9th. Piper Sandler reaffirmed an overweight rating and issued a $28.00 price target on shares of Immunic in a report on Tuesday, July 16th. StockNews.com raised shares of Immunic from a sell rating to a hold rating in a report on Tuesday, August 13th. B. Riley began coverage on shares of Immunic in a research note on Tuesday, August 27th. They issued a buy rating and a $6.00 target price for the company. Finally, Leerink Partnrs raised shares of Immunic to a strong-buy rating in a research note on Monday, September 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Immunic currently has a consensus rating of Buy and an average target price of $11.20.

Immunic Stock Performance

IMUX opened at $1.60 on Monday. The firm has a market cap of $144.13 million, a price-to-earnings ratio of -0.87 and a beta of 1.82. The firm’s 50-day simple moving average is $1.41 and its 200-day simple moving average is $1.31. Immunic has a twelve month low of $0.95 and a twelve month high of $1.92.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same quarter in the prior year, the firm earned ($0.54) EPS. As a group, sell-side analysts anticipate that Immunic will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC bought a new position in Immunic in the first quarter valued at approximately $25,000. Sierra Summit Advisors LLC bought a new position in shares of Immunic in the 4th quarter worth $487,000. Ikarian Capital LLC grew its stake in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the period. Vanguard Group Inc. grew its stake in shares of Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in Immunic in the first quarter valued at about $9,266,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.